We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Poolbeg Pharma (POLB) Ord Shares

Sell:7.60p Buy:7.80p 0 Change: No change
Market closed |  Prices as at close on 21 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.60p
Buy:7.80p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.60p
Buy:7.80p
Change: No change
Market closed |  Prices as at close on 21 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.

Contact details

Address:
42 New Road
LONDON
E1 2AX
United Kingdom
Telephone:
+44 (020) 71831499
Website:
https://www.poolbegpharma.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 18 September 2024 18/09/24
AGM 13 June 2024 13/06/24
Annual report 09 May 2024 09/05/24
Final results 30 April 2024 30/04/24

General stock information

EPIC:
POLB
ISIN:
GB00BKPG7Z60
Market cap:
£38.00 million
Shares in issue:
500.00 million
Sector:
No specific Industry
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Cathal Friel
    Executive Chairman of the Board
  • Jeremy Skillington
    Chief Executive Officer, Executive Director
  • Ian Oconnell
    Chief Financial Officer, Executive Director
  • John Mcevoy
    Senior Vice President, Chief Legal Officer
  • Laura Maher
    Vice President - Clinical Operations
  • David Allmond
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.